» Articles » PMID: 37462785

The Mitochondrially Targeted Peptide Elamipretide (SS-31) Improves ADP Sensitivity in Aged Mitochondria by Increasing Uptake Through the Adenine Nucleotide Translocator (ANT)

Abstract

Aging muscle experiences functional decline in part mediated by impaired mitochondrial ADP sensitivity. Elamipretide (ELAM) rapidly improves physiological and mitochondrial function in aging and binds directly to the mitochondrial ADP transporter ANT. We hypothesized that ELAM improves ADP sensitivity in aging leading to rescued physiological function. We measured the response to ADP stimulation in young and old muscle mitochondria with ELAM treatment, in vivo heart and muscle function, and compared protein abundance, phosphorylation, and S-glutathionylation of ADP/ATP pathway proteins. ELAM treatment increased ADP sensitivity in old muscle mitochondria by increasing uptake of ADP through the ANT and rescued muscle force and heart systolic function. Protein abundance in the ADP/ATP transport and synthesis pathway was unchanged, but ELAM treatment decreased protein s-glutathionylation incuding of ANT. Mitochondrial ADP sensitivity is rapidly modifiable. This research supports the hypothesis that ELAM improves ANT function in aging and links mitochondrial ADP sensitivity to physiological function. ELAM binds directly to ANT and ATP synthase and ELAM treatment improves ADP sensitivity, increases ATP production, and improves physiological function in old muscles. ADP (adenosine diphosphate), ATP (adenosine triphosphate), VDAC (voltage-dependent anion channel), ANT (adenine nucleotide translocator), H (proton), ROS (reactive oxygen species), NADH (nicotinamide adenine dinucleotide), FADH (flavin adenine dinucleotide), O (oxygen), ELAM (elamipretide), -SH (free thiol), -SSG (glutathionylated protein).

Citing Articles

Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers.

Liu S, Faitg J, Tissot C, Konstantopoulos D, Laws R, Bourdier G iScience. 2025; 28(2):111814.

PMID: 40034121 PMC: 11875685. DOI: 10.1016/j.isci.2025.111814.


Pioneering Advances and Innovative Applications of Mesoporous Carriers for Mitochondria-Targeted Therapeutics.

Al Tahan M, Al Tahan S Br J Biomed Sci. 2024; 81:13707.

PMID: 39624468 PMC: 11608979. DOI: 10.3389/bjbs.2024.13707.


Heart Failure: A Deficiency of Energy-A Path Yet to Discover and Walk.

Paraskevaidis I, Kourek C, Farmakis D, Tsougos E Biomedicines. 2024; 12(11).

PMID: 39595155 PMC: 11592498. DOI: 10.3390/biomedicines12112589.


Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

Karaa A, Bertini E, Carelli V, Cohen B, Ennes G, Falk M Orphanet J Rare Dis. 2024; 19(1):431.

PMID: 39574155 PMC: 11583740. DOI: 10.1186/s13023-024-03421-5.


The mitochondrial-targeted peptide therapeutic elamipretide improves cardiac and skeletal muscle function during aging without detectable changes in tissue epigenetic or transcriptomic age.

Mitchell W, Pharaoh G, Tyshkovskiy A, Campbell M, Marcinek D, Gladyshev V bioRxiv. 2024; .

PMID: 39554099 PMC: 11565897. DOI: 10.1101/2024.10.30.620676.


References
1.
Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

2.
Whitson J, Bitto A, Zhang H, Sweetwyne M, Coig R, Bhayana S . SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020; 19(10):e13213. PMC: 7576234. DOI: 10.1111/acel.13213. View

3.
Chiao Y, Zhang H, Sweetwyne M, Whitson J, Ting Y, Basisty N . Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. Elife. 2020; 9. PMC: 7377906. DOI: 10.7554/eLife.55513. View

4.
Ahn B, Pharaoh G, Premkumar P, Huseman K, Ranjit R, Kinter M . Nrf2 deficiency exacerbates age-related contractile dysfunction and loss of skeletal muscle mass. Redox Biol. 2018; 17:47-58. PMC: 6006677. DOI: 10.1016/j.redox.2018.04.004. View

5.
Ydfors M, Hughes M, Laham R, Schlattner U, Norrbom J, Perry C . Modelling in vivo creatine/phosphocreatine in vitro reveals divergent adaptations in human muscle mitochondrial respiratory control by ADP after acute and chronic exercise. J Physiol. 2015; 594(11):3127-40. PMC: 4887669. DOI: 10.1113/JP271259. View